---
schema_version: "secwatch.filing_event.v1"
accession: "0000886163-24-000013"
form_type: "8-K"
ticker: "LGND"
cik: "0000886163"
company_name: "LIGAND PHARMACEUTICALS INC"
filed_at: "2024-04-19T23:59:59+00:00"
generated_at: "2026-06-03T17:45:34.564423+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Ligand adopts amended bylaws for universal proxy rules and DGCL updates

## Summary
- Board approved Fifth Amended and Restated Bylaws on April 17, 2024.
- Updates include requirements for stockholder nominations under Rule 14a-19 (universal proxy).
- Clarifies broker non-votes have no effect; abstentions count as votes against.
- Revisions reflect changes to Delaware General Corporation Law on electronic notices and stockholder lists.
- Also makes conforming changes to stockholder proposal and nomination procedures.

## SEC filing metadata
- accession: 0000886163-24-000013
- form_type: 8-K
- ticker: LGND
- cik: 0000886163
- company_name: LIGAND PHARMACEUTICALS INC
- filed_at: 2024-04-19T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/886163/000088616324000013/0000886163-24-000013-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/886163/000088616324000013/lgnd-20240417.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000886163-24-000013
- JSON: https://secwatch.observer/filing/0000886163-24-000013.json
- Plain text: https://secwatch.observer/filing/0000886163-24-000013.txt

## Key facts
- Governance Changes
  LIGAND PHARMACEUTICALS INC: Adopted Fifth Amended and Restated Bylaws with updates for universal proxy rules, DGCL amendments, and other revisions (effective 2024-04-17).
  - Change: bylaw amendment
  - Effective: 2024-04-17
  source text: On April 17, 2024, the Board of Directors (the “Board”) of Ligand Pharmaceuticals Incorporated (the “Company”), in connection with the Securities and Exchange Commission’s revisions to the Securities Exchange Act of 1934, as amended (the "Exchange Act") regarding universal proxy cards, changes to the Delaware General Corporation Law (the "DGCL"), and a periodic review of corporate governance matters, approved the amendment and restatement of the Company’s Fourth Amended and Restated Bylaws, as amended (the “Fifth Amended and Restated Bylaws”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/886163/000088616324000013/0000886163-24-000013-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.